ADVERTISMENT
 
Welcome to AVAHO Oncology and Hematology Updates, a resource for hematologists and oncologists working in the VA! This microsite features highlights from the 2012 AVAHO Annual Meeting including the program and schedule, abstracts, and video highlights of poster presentations. Also available are Federal Practitioner’s 2011 and 2012 special issues, Clinical Advances in Oncology, which provide updates on cancers of special importance to veterans. Additional updates will be posted after the meeting.

Peter T. Silberstein, MD
Site EIC and Immediate Past President, Association of VA Hematology/Oncology (AVAHO)

For more oncology resources, please visit www.oncologypractice.com.
 
New Clinical Resources
 
 
Clinical Advances in Oncology
Please click here to access Federal Practitioner's special issues in oncology.
 
Topic Collection: Cancer
More Topic Collection: Cancer...
 
Fast Facts
Please click here to access Federal Practitioner's Fast Facts on Cancer
 
Abstracts
 
SPEED OF CARE: GETTING PATIENTS INTO CHEMOTHERAPY APPOINTMENTS MORE QUICKLY AND EFFICIENTLY
COMBINED INTENSITY MODULATED RADIATION THERAPY AND CYBERKNIFE RADIOSURGERY FOR SPINAL METASTASIS
TIME TO FIRST COURSE TREATMENT OF NON–SMALL‐CELL LUNG CANCER: HOW IS THE VETERANS AFFAIRS SYSTEM DOING
THE USE OF ADJUVANT CHEMOTHERAPY FOR STAGE III COLON CANCER, CONSIDERING INCOME, RACE, AGE, AND INSURANCE STATUS
More Abstracts...
 
New Oncology Practice News Feed Please Check Often for Updates
 
 
New Meeting Coverage
 
What is Personalized Medicine for Patients with Lymphoma?
 
Colorectal Cancer: A Lifelong Pursuit of Diagnosis, Surveillance, and Management
Dr. Henry T. Lynch
 
How do we manage Multiple Myeloma in 2012? Robert A. Kyle, MD
 
 
New Audio/Video
 
Please click here for a welcome message from Dr. Silberstein and poster presentations from the AVAHO Annual Meeting.
 
 
 
 
New News Releases
 
4/16/13 US panel recommends tamoxifen, Evista to prevent breast cancer in some women
4/10/13: Lilly Debuts Early Oncology Pipeline Data At AACR Annual Meeting
4/1/13 Analysis: Women who took HRT no less likely to die from breast cancer than peers
3/15/13 Novartis compound LDK378 receives FDA Breakthrough Therapy designation for ALK+ non-small cell lung cancer
More News Releases...
 
 
ADVERTISMENT
 
ADVERTISMENT
 
ADVERTISMENT
 
 
Updated: April 29,2013